177 related articles for article (PubMed ID: 23471749)
1. The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia.
Teo ZL; Sawyer SD; James PA; Mitchell G; Trainer AH; Lindeman GJ; Shackleton K; Cicciarelli L; Southey MC
Fam Cancer; 2013 Dec; 12(4):587-95. PubMed ID: 23471749
[TBL] [Abstract][Full Text] [Related]
2. A PALB2 mutation associated with high risk of breast cancer.
Southey MC; Teo ZL; Dowty JG; Odefrey FA; Park DJ; Tischkowitz M; Sabbaghian N; Apicella C; Byrnes GB; Winship I; Baglietto L; Giles GG; Goldgar DE; Foulkes WD; Hopper JL;
Breast Cancer Res; 2010; 12(6):R109. PubMed ID: 21182766
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
[TBL] [Abstract][Full Text] [Related]
4. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
[TBL] [Abstract][Full Text] [Related]
5. PALB2: a novel inactivating mutation in a Italian breast cancer family.
Balia C; Sensi E; Lombardi G; Roncella M; Bevilacqua G; Caligo MA
Fam Cancer; 2010 Dec; 9(4):531-6. PubMed ID: 20852946
[TBL] [Abstract][Full Text] [Related]
6. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Southey MC; Goldgar DE; Winqvist R; Pylkäs K; Couch F; Tischkowitz M; Foulkes WD; Dennis J; Michailidou K; van Rensburg EJ; Heikkinen T; Nevanlinna H; Hopper JL; Dörk T; Claes KB; Reis-Filho J; Teo ZL; Radice P; Catucci I; Peterlongo P; Tsimiklis H; Odefrey FA; Dowty JG; Schmidt MK; Broeks A; Hogervorst FB; Verhoef S; Carpenter J; Clarke C; Scott RJ; Fasching PA; Haeberle L; Ekici AB; Beckmann MW; Peto J; Dos-Santos-Silva I; Fletcher O; Johnson N; Bolla MK; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Marme F; Burwinkel B; Yang R; Guénel P; Truong T; Menegaux F; Sanchez M; Bojesen S; Nielsen SF; Flyger H; Benitez J; Zamora MP; Perez JI; Menéndez P; Anton-Culver H; Neuhausen S; Ziogas A; Clarke CA; Brenner H; Arndt V; Stegmaier C; Brauch H; Brüning T; Ko YD; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Antonenkova NN; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Spurdle AB; Investigators K; ; Wauters E; Smeets D; Beuselinck B; Floris G; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Olson JE; Vachon C; Pankratz VS; McLean C; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Kristensen V; Alnæs GG; Zheng W; Hunter DJ; Lindstrom S; Hankinson SE; Kraft P; Andrulis I; Knight JA; Glendon G; Mulligan AM; Jukkola-Vuorinen A; Grip M; Kauppila S; Devilee P; Tollenaar RA; Seynaeve C; Hollestelle A; Garcia-Closas M; Figueroa J; Chanock SJ; Lissowska J; Czene K; Darabi H; Eriksson M; Eccles DM; Rafiq S; Tapper WJ; Gerty SM; Hooning MJ; Martens JW; Collée JM; Tilanus-Linthorst M; Hall P; Li J; Brand JS; Humphreys K; Cox A; Reed MW; Luccarini C; Baynes C; Dunning AM; Hamann U; Torres D; Ulmer HU; Rüdiger T; Jakubowska A; Lubinski J; Jaworska K; Durda K; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Swerdlow A; Ashworth A; Orr N; Jones M; González-Neira A; Pita G; Alonso MR; Álvarez N; Herrero D; Tessier DC; Vincent D; Bacot F; Simard J; Dumont M; Soucy P; Eeles R; Muir K; Wiklund F; Gronberg H; Schleutker J; Nordestgaard BG; Weischer M; Travis RC; Neal D; Donovan JL; Hamdy FC; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Schaid DJ; Kelley JL; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Butterbach K; Park J; Kaneva R; Batra J; Teixeira MR; Kote-Jarai Z; Olama AA; Benlloch S; Renner SP; Hartmann A; Hein A; Ruebner M; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Lambretchs S; Doherty JA; Rossing MA; Nickels S; Eilber U; Wang-Gohrke S; Odunsi K; Sucheston-Campbell LE; Friel G; Lurie G; Killeen JL; Wilkens LR; Goodman MT; Runnebaum I; Hillemanns PA; Pelttari LM; Butzow R; Modugno F; Edwards RP; Ness RB; Moysich KB; du Bois A; Heitz F; Harter P; Kommoss S; Karlan BY; Walsh C; Lester J; Jensen A; Kjaer SK; Høgdall E; Peissel B; Bonanni B; Bernard L; Goode EL; Fridley BL; Vierkant RA; Cunningham JM; Larson MC; Fogarty ZC; Kalli KR; Liang D; Lu KH; Hildebrandt MA; Wu X; Levine DA; Dao F; Bisogna M; Berchuck A; Iversen ES; Marks JR; Akushevich L; Cramer DW; Schildkraut J; Terry KL; Poole EM; Stampfer M; Tworoger SS; Bandera EV; Orlow I; Olson SH; Bjorge L; Salvesen HB; van Altena AM; Aben KK; Kiemeney LA; Massuger LF; Pejovic T; Bean Y; Brooks-Wilson A; Kelemen LE; Cook LS; Le ND; Górski B; Gronwald J; Menkiszak J; Høgdall CK; Lundvall L; Nedergaard L; Engelholm SA; Dicks E; Tyrer J; Campbell I; McNeish I; Paul J; Siddiqui N; Glasspool R; Whittemore AS; Rothstein JH; McGuire V; Sieh W; Cai H; Shu XO; Teten RT; Sutphen R; McLaughlin JR; Narod SA; Phelan CM; Monteiro AN; Fenstermacher D; Lin HY; Permuth JB; Sellers TA; Chen YA; Tsai YY; Chen Z; Gentry-Maharaj A; Gayther SA; Ramus SJ; Menon U; Wu AH; Pearce CL; Van Den Berg D; Pike MC; Dansonka-Mieszkowska A; Plisiecka-Halasa J; Moes-Sosnowska J; Kupryjanczyk J; Pharoah PD; Song H; Winship I; Chenevix-Trench G; Giles GG; Tavtigian SV; Easton DF; Milne RL
J Med Genet; 2016 Dec; 53(12):800-811. PubMed ID: 27595995
[TBL] [Abstract][Full Text] [Related]
7. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
8. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
[TBL] [Abstract][Full Text] [Related]
11. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
13. Breast-cancer risk in families with mutations in PALB2.
Antoniou AC; Casadei S; Heikkinen T; Barrowdale D; Pylkäs K; Roberts J; Lee A; Subramanian D; De Leeneer K; Fostira F; Tomiak E; Neuhausen SL; Teo ZL; Khan S; Aittomäki K; Moilanen JS; Turnbull C; Seal S; Mannermaa A; Kallioniemi A; Lindeman GJ; Buys SS; Andrulis IL; Radice P; Tondini C; Manoukian S; Toland AE; Miron P; Weitzel JN; Domchek SM; Poppe B; Claes KB; Yannoukakos D; Concannon P; Bernstein JL; James PA; Easton DF; Goldgar DE; Hopper JL; Rahman N; Peterlongo P; Nevanlinna H; King MC; Couch FJ; Southey MC; Winqvist R; Foulkes WD; Tischkowitz M
N Engl J Med; 2014 Aug; 371(6):497-506. PubMed ID: 25099575
[TBL] [Abstract][Full Text] [Related]
14. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
15. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
16. PALB2 mutations in familial breast and pancreatic cancer.
Hofstatter EW; Domchek SM; Miron A; Garber J; Wang M; Componeschi K; Boghossian L; Miron PL; Nathanson KL; Tung N
Fam Cancer; 2011 Jun; 10(2):225-31. PubMed ID: 21365267
[TBL] [Abstract][Full Text] [Related]
17. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
[TBL] [Abstract][Full Text] [Related]
18. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Rahman N; Seal S; Thompson D; Kelly P; Renwick A; Elliott A; Reid S; Spanova K; Barfoot R; Chagtai T; Jayatilake H; McGuffog L; Hanks S; Evans DG; Eccles D; ; Easton DF; Stratton MR
Nat Genet; 2007 Feb; 39(2):165-7. PubMed ID: 17200668
[TBL] [Abstract][Full Text] [Related]
19. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
20. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
Casadei S; Norquist BM; Walsh T; Stray S; Mandell JB; Lee MK; Stamatoyannopoulos JA; King MC
Cancer Res; 2011 Mar; 71(6):2222-9. PubMed ID: 21285249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
